In this episode of MedTech Global Insights, we demystify one of the most critical documents for European market access: the Clinical Evaluation Report (CER). Navigating the stringent requirements of MEDDEV 2.7/1 revision 4 is a major challenge for many MedTech companies, often leading to costly delays and rejections from Notified Bodies. We move beyond theory to provide actionable advice. This episode breaks down the four most common and critical failure points in CER writing: conducting a superficial "state-of-the-art" analysis, failing to rigorously justify equivalence, performing a non-systematic literature search, and inadequately appraising clinical data. We provide concrete examples of what Notified Bodies expect and how to build a robust, defensible clinical argument for your device. A common pain point we explore: Imagine your company has developed an innovative bone graft substitute. You've spent months compiling a CER, claiming equivalence to a market leader to avoid a costly clinical trial. However, the Notified Body rejects it, stating your data on the material's resorption rate and biomechanical properties is insufficient to prove equivalence. Your market launch is now delayed by at least a year, and you're facing an unplanned, multi-million dollar clinical study. This episode teaches you how to avoid that scenario. Key Takeaways: - Is my "State-of-the-Art" section a true clinical analysis or just a list of competitors? - How can I prove technical, biological, and clinical equivalence so rigorously that I can avoid a new clinical trial? - What specific elements must be included in a literature search protocol to make it "systematic" and audit-proof? - How do I properly weigh and appraise different levels of clinical evidence? - What is the direct link between my risk management file and the data presented in my CER? - Why is a large volume of data not always a good thing in a clinical evaluation? - What are the most common gaps that Notified Bodies find in CER submissions today? Contact us for a consultation at [email protected] or visit https://pureglobal.com/
Fler avsnitt av MedTech Global Insights
Visa alla avsnitt av MedTech Global InsightsMedTech Global Insights med Ran Chen finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
